Natera's Signatera outperforms AMERK in skin cancer recurrence study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
July 22, 2026 6:00 AM EDTSignatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a... More
